Biatrial Versus Left Atrial Maze Ablation During Cardiac Valve Surgery for Persistent Atrial Fibrillation: The ABLATION Trial
In brief
Biatrial maze keeps 79% arrhythmia-free after rheumatic valve surgery
In a randomized trial of 323 patients with persistent atrial fibrillation undergoing rheumatic valve surgery, 78.7% after biatrial maze ablation were free of atrial tachyarrhythmias at 12 months, versus 68.6% after left atrial ablation. Pacemaker implantation rates were similarly low in both groups, supporting biatrial ablation for this population; whether the advantage extends to other valve surgery patients remains unknown.
- Journal
- Circulation (Q1)
- Published
- 16 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Zhongchen Li, Chunyu Yu, Haojie Li, Yang Wang, Yongfeng Shao, Jinping Liu, et al.
- PMID
- 43038430
- DOI
- 10.1161/CIRCULATIONAHA.126.083005
Why clinicians should know about it
- Picked for Cardiology and Cardiovascular Medicine (paper of the day, 17 November 2026): Randomized trial compares surgical maze strategies during valve surgery
Abstract
BACKGROUND: Guidelines recommend concomitant surgical ablation during cardiac surgery in patients with atrial fibrillation (AF). However, the optimal lesion set remains uncertain, with ongoing debate regarding the relative benefits and risks of biatrial versus left atrial (LA) maze ablation. METHODS: In this multicenter, randomized, single-blind trial, patients with persistent or long-standing persistent AF undergoing rheumatic mitral valve surgery, with or without concomitant cardiac surgical procedures, were randomly assigned in a 1:1 ratio to undergo biatrial or LA maze ablation. The biatrial group underwent a complete Cox-Maze IV procedure; the LA group received a left-sided maze lesion set. To ensure standardization and consistency of the ablation procedures, surgeons underwent pretrial training and certification, and all procedures were videorecorded and centrally reviewed. The primary outcome was freedom from atrial tachyarrhythmias lasting >30 seconds without antiarrhythmic drugs within 12 months. The key secondary end point was freedom from permanent pacemaker implantation. RESULTS: All 323 randomized patients were included in the intention-to-treat analysis (mean age, 56.5 years; 72.1% women; mean LA diameter, 51.9 mm). At 12 months, 78.7% of patients (129 of 164) in the biatrial group and 68.6% (109 of 159) in the LA group were free from atrial tachyarrhythmias (adjusted difference, 10.7% [1-sided lower 95% CI, 3%]; P=0.01). Freedom from permanent pacemaker implantation was noted in 97.0% (159 of 164) of the biatrial group and 98.1% (156 of 159) of the LA group, meeting the predefined noninferiority criterion with a margin of -5% (adjusted difference, -1.1% [1-sided lower 95% CI, -3.9%]; Pnoninferiority=0.01). CONCLUSIONS: Among patients with persistent or long-standing persistent AF undergoing rheumatic cardiac valve surgery, biatrial maze ablation was superior to LA maze ablation in reducing recurrent atrial tachyarrhythmias, while maintaining noninferiority with respect to permanent pacemaker implantation. These findings provide direct evidence to inform lesion-set selection for surgical ablation during cardiac surgery. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05021601.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.